MicroVention Announces Clinical Publication of SOFAST: SOFIA™ Aspiration System as First Line Technique in Treating Acute Ischemic Stroke
MicroVention, Inc., a global neurovascular company and wholly owned subsidiary of Terumo Corporation, announced the publication of the SOFIA™ Aspiration System as first-line Technique (SOFAST): A prospective, multicenter study to assess the efficacy and safety of the 6 French SOFIA™ Flow Plus Aspiration Catheter for endovascular stroke thrombectomy, recently published in the Journal of NeuroInterventional Surgery (JNIS).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240709802645/en/
MicroVention Announces Clinical Publication of SOFAST: SOFIA™ Aspiration System as First Line Technique in Treating Acute Ischemic Stroke (Graphic: Business Wire)
The SOFAST study assessed the SOFIA™ Flow Plus Aspiration Catheter (SOFIA 6F) for treating acute ischemic stroke caused by large vessel occlusion. This U.S. Prospective, multicenter study involved 108 patients and aimed to confirm the catheter’s safety, speed and effectiveness in revascularization. The long-standing legacy of SOFIA is reinforced by the important data points observed in this publication emphasizing the following:
- Speed: 12-minute median groin puncture to clot contact time and 17-minute median groin puncture to recanalization time.
- Efficacy: 75% First Pass mTICI≥2b using SOFIA 6F.
- Safety: 0% embolization to new territories and symptomatic intracranial hemorrhage rate within 24h.
- Clinical Outcomes: 66.7% of patients experienced good functional outcomes at 90 days.
Please reference the publication for a comprehensive set of data points and outcomes.
“The efficacy and safety data from this prospective, multi-center, independent core-lab adjudicated SOFAST study are very impressive and sets a new innovation standard. High rates of mTICI≥2b (97.2%) revascularization at the procedure end, 70.4% rate of mTICI 2c or better after the first pass, median time to recanalization of 17 minutes and 66.7% rate of good clinical outcomes are amongst the very best metrics reported with contemporary thrombectomy devices,” said Dr. Dheeraj Gandhi, Vice Chairman for Academic Affairs; Director, Interventional Neuroradiology; Director, CMIT Center (Center for Metabolic Imaging and Therapeutics); Professor of Radiology, Neurology and Neurosurgery, University of Maryland School of Medicine.
“The SOFAST Study further underscores that our SOFIA™ Aspiration Catheters have set the standard for more than a decade with its renowned trackability, speed and now with further proven clinical performance,” said Carsten Schroeder, President and CEO, MicroVention, Inc. “We will continue to participate in critical clinical research such as SOFAST, work side-by-side with leading physicians around the world to identify the evolving needs in patient care, and then transform those insights into innovative technologies that help to save patient lives.”
MicroVention also recently celebrated a decade of legacy innovation commemorating the anniversary of SOFIA™ and SOFIA™ Flow Plus Aspiration Catheters, with more than half a million worldwide procedures performed across 170 countries, and 30+ articles published globally since it was first introduced more than ten years ago. Designed for speed to target, clot engagement, kink resistance and a confident first pass, SOFIA Flow Plus Aspiration Catheters continue to set the pace in treating acute ischemic stroke.
From access to revascularization, MicroVention now offers a fully integrated and streamlined portfolio of stroke solutions including SOFIA™, SOFIA™ Flow Plus Aspiration Catheters, as well as ERIC™ Retrieval Device, BOBBY™ Balloon Guide Catheter, WEDGE™ Microcatheter, HEADWAY™ Microcatheters and TRAXCESS™ Guidewires.
About MicroVention, Inc.
Founded in 1997, MicroVention develops and markets medical devices that enable or significantly improve treatment of cerebrovascular diseases. In 2006, Terumo Corporation, a major worldwide medical device company headquartered in Tokyo, Japan, acquired MicroVention into their family of Companies. Terumo’s acquisition of MicroVention allowed both Companies to leverage their unique, proprietary technologies toward an increased focus on treating cerebrovascular diseases. Headquartered in California, MicroVention products are today sold in more than seventy countries through a direct sales organization alongside strategic distribution partnerships. Manufacturing facilities are in Aliso Viejo, California and San José, Costa Rica. For more information on MicroVention, please visit www.microvention.com.
About Terumo Corporation
Terumo (TSE:4543) is a global leader in medical technology and has been committed to "Contributing to Society through Healthcare" for 100 years. Based in Tokyo and operating globally, Terumo employs more than 30,000 Associates worldwide to provide innovative medical solutions in more than 160 countries and regions. The company started as a Japanese thermometer manufacturer and has been supporting healthcare ever since. Now, its extensive business portfolio ranges from vascular intervention and cardio-surgical solutions, blood transfusion and cell therapy technology, to medical products essential for daily clinical practice. Terumo will further strive to be of value to patients, medical professionals, and society at large. For more information on Terumo, please visit www.terumo.com/about/profile.
** Editor’s Note: For a Clinical Glossary of Terms, please visit https://www.microvention.com/clinical-education/glossary.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240709802645/en/
Contacts
Media Contact:
Christine McCullough
Global Corporate Communications
MicroVention, Inc.
+ 1 714 206 9800
christine.mccullough@microvention.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Analyze Contracts Like a Lawyer - Wordsmith’s First Pass Unlocks Legal Insight for Everyone8.11.2024 00:54:00 EET | Press release
“Contracts often hold up business because legal teams are stretched too thin,” said Ross McNairn, CEO of Wordsmith. “First Pass allows anyone from the legal, commercial or other teams to quickly identify risks and key terms, helping move things forward.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241108164624/en/ Wordsmith's First Pass lets you review contracts in minutes, not hours. (Graphic: Business Wire) This is a glimpse at the future of legal AI agents. Taking a very specific task end-to-end and making it trivial for anyone to trigger. Try It for Free Users can access First Pass for free by creating an account at wordsmith.ai and then uploading the relevant agreement to the web, or simply email standard agreements—like NDAs—to nda@wordsmith.ai. Over the coming weeks, Wordsmith will be expanding this to many other agreement types. End-to-End AI Analysis—More Than Just Contracting What makes First Pass revolutionary
Maravai LifeSciences Plans to Acquire DNA and RNA Business of Officinae Bio, Advancing Support for Innovative Nucleic Acid Research7.11.2024 23:01:00 EET | Press release
Maravai LifeSciences, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, announced that it has signed an agreement to acquire the DNA and RNA business of Officinae Bio. The acquisition is expected to expand Maravai and TriLink BioTechnologies' ability to assist customers in developing innovative nucleic acid-based therapies. Based in Venice, Italy, Officinae Bio is a privately held technology company with a proprietary digital platform to support the biological design of therapeutics. The novel technology enables rapid prototyping of mRNA candidates to test diverse combinations of CAP analogs, chemistry modifications, and sequence designs for client discovery programs. Officinae Bio’s portfolio of technology and services complements Maravai’s nucleic acid production services and is expected to provide customers with significant benefits as they bring new and innovative therapies to patients in need. “Officinae Bio’s uniqu
IonQ to Increase Performance and Scale of Quantum Computers with Photonic Integrated Circuits in Collaboration with imec7.11.2024 23:00:00 EET | Press release
IonQ (NYSE: IONQ), a leader in the quantum computing industry, announced today that it is developing photonic integrated circuits (PICs) and chip-scale ion trap technology for trapped ion quantum computing in partnership with imec, a world-renowned R&D center in nanoelectronics and digital technologies. By optimizing the design, production, and integration of chip-scale photonic devices and ion traps for scalable and high-performance quantum computers, the developments aim to push the boundaries of quantum computing performance. Traditional trapped ion quantum computing approaches rely on bulk optics for laser light modulation, delivery, and photon collection. By moving traditional bulk optical components into integrated photonic devices, IonQ aims to reduce overall hardware system size and cost, increase qubit count, and improve system performance and robustness. Chip-scale optical technologies and IonQ’s tight integration with imec’s trap manufacturing and packing are expected to ope
BM3EAC Corp. Termination of Discussions Regarding Proposed Business Combination With Arkon Energy7.11.2024 19:29:00 EET | Press release
BM3EAC Corp. (the “Company”), a shell company incorporated under the laws of the Cayman Islands as an exempted company with limited liability and listed on Euronext Amsterdam, the regulated market operated by Euronext Amsterdam N.V., hereby announces the termination of the discussions with Arkon Energy Ohio LLC (now Arkon Energy US Holdco LLC) (“Arkon”) regarding a potential transaction, including a business combination, initially announced on 21 February 2024 (the “Potential Business Combination”). After careful consideration, the Company and Arkon have determined that the current market conditions are not conducive to proceeding with the Potential Business Combination. IMPORTANT INFORMATION This press release may contain information that qualifies or may have qualified as inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation. DISCLAIMER This announcement is not for distribution or release, directly or indirectly, and should not be distributed in or s
Brenus Pharma Publishes Promising Proof of Concept Results of their Therapeutic Platform in the Scientific Frontiers in Oncology Journal. (1)7.11.2024 19:00:00 EET | Press release
Brenus Pharma has announced the publication of a scientific article describing its new “off-the-shelf” cancer treatment in “Frontiers in Oncology” Section Cancer Immunity and Immunotherapy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241107407975/en/ Brenus’ platform mimics patients’ relapsing conditions in lab, to educate the immune system against tumors evolution with the largest panel of multi-specific targets available. Its lead candidate is a proteomic-guided immunotherapy, designed to treat patients with advanced or metastatic CRC. Results show that the murine surrogate treatment inhibits tumor growth and improves survival of treated mice bearing tumors. It has also shown efficacy in a PD1-resistant model, with an increased infiltration of CD8+T cells in cold tumors, associated with strong safety data. Indeed, the treatment’s in vitro exposition to standards of careinduces the expression of cancer-related proteins l
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom